PRQR

ProQR Therapeutics N.V. Ordinary Shares (PRQR) | Rumor.io

ProQR Therapeutics

PRQR

Attention (50-day avg)0.01%

Attention rank (50-day avg)#450

Bullish sentiment (50-day avg)97%

Price to earnings ratio-4.15

Market capitalization232.8M

Earnings per share-0.45

Dividend yield (TTM)—

Revenue (annual)15.9M

Net income (annual)-42.2M

Social

What share of all stock conversation is about PRQR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0.02% +0.02	0% 0

Aug 20

BofA initiates coverage of PRQR with a Buy rating and a $8 target, citing positive AX-0810 Phase 1 data and strong RNA-editing upside.
The initiation of coverage by BofA is seen as a positive validation of PRQR's technology, with AX-0810 delivering the first human validation of Axiomer RNA tech.
Insiders have been making purchases in PRQR, which may indicate a reversal or bottoming in the stock.

Generated by AI

Sentiment

Of the messages about PRQR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	98.08% -1.92	96.25% -1.16	91.45% +6.73
Bearish	—	1.92% new	3.75% +1.16	8.55% -6.73

Bullish· Oct 23

$PRQR's strong pricing on its offering and Lilly's private placement provide a cash-rich platform for growth.
Lilly's decision to add more $PRQR shares to their pile, potentially based on inside information about preclinical results, is a bullish sign.
$PRQR's market capitalization remains undervalued compared to similar companies, with a strong close and demand that could drive the stock back up to its offering price.

Bearish· Oct 16

$PRQR has a history of being rejected at $4.00, potentially setting up an explosion through the $4.10 mark.
The company's 300 million shelf offering has not been raised, which could lead to a significant increase in the number of shares available.
The stock has been subject to aggressive short selling, with some traders covering their positions at lower prices.

Generated by AI

Topics

Of the messages about PRQR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	89.23%
Technical Analysis	—	0%	0%	3.95%
Analysts	—	0%	0%	6.68%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0.15%
Macro	—	0%	0%	0%

Analysts· Feb 14

Chardan Capital maintains a Buy rating for ProQR Therapeutics with a lower price target of $8.
JMP Securities lowers the price target for ProQR Therapeutics to $8 with a Market Outperform rating.
Analysts polled by Capital IQ have an average rating of Outperform for ProQR Therapeutics with price targets ranging from $3 to $20.

Announcements· Jun 25

ProQR Therapeutics ($PRQR) announces positive Phase 1 target engagement data for AX-0810, establishing the first clinical validation of its Axiomer RNA editing platform.
The company raises $50M in a registered direct offering priced at $1.81/share, with Eli Lilly participating in a concurrent private placement to maintain its ownership stake.
The positive data and funding raise demonstrate strong confidence in ProQR's RNA editing platform, with potential for faster pipeline progress and increased value for the company.

Technical Analysis· Dec 22

$PRQR is a high-volume stock that often holds its open level and closes green by 70% of the time.
$PRQR has a strong trend and has curled for a push through the Volume Weighted Average Price (VWAP).
$PRQR is forming a cup and handle pattern, with a potential target of $3.10-$9.00.

Generated by AI

Community

Of the messages about PRQR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	95.08%	1.25%	23.35%
Newcomers	—	4.92%	98.75%	76.65%

Regulars· Oct 16

ProQR's cash reserves are sufficient to last until 2026, and the company is on the verge of releasing preclinical data that will validate its platform and potentially exceed previous highs.
ProQR's ownership of key patents and its position as the inventor of RNA editing technology make it a significant player in the ADAR/RNA editing space, and its partnership with Lilly may provide a competitive advantage.
ProQR is expected to enter clinical trials in the current quarter or Q1, and its collaboration with Lilly and potential acquisition by Alnylam may be key factors in its future success.

Newcomers· Apr 9

$PRQR is up 12% after highlighting pipeline progress, including the selection of AX-0810 for Phase 2 biliary atresia trials.
ProQR's pipeline expansion is expected to bring multiple clinical catalysts, with target engagement data for AX-0810 due this quarter and a CTA for AX-0811 in mid-2026.
The company's investor and analyst event outlined its pipeline progress, focusing on key developments in its clinical trials and therapeutic pipeline.

Generated by AI

News

ProQR names AI executives as clinical data nears

6d agoInvesting.com

Obesity Market to Witness Strong Growth and Significant Market Expansion by 2036 – DelveInsight | Rhythm Pharma, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical

19d agoBarchart.com

ProQR doses first participant in AX-0811 phase 1 trial

20d agoInvesting.com

ProQR at Cantor conference: RNA editing pipeline gains speed

21d agoInvesting.com

ProQR Therapeutics Doses First Participant in Phase 1 Trial of Liver Disease Treatment

ProQR Therapeutics (PRQR) said Wednesday it has dosed the first participant in a phase 1 trial of AX

21d agoYahoo Finance

ProQR to Participate in Upcoming Investor Conferences in September 2026

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage ...

27d agomarkets.businessinsider.com

Also Discussed

Investors talking about PRQR also mention

#	Name	Attention
1	Galapagos NV American Depositary ReceiptGLPG	0%0
2	Wave Life Sciences Ltd.WVE	0%+0
3	AFMD - Affimed N.V.	——
4	Arrowhead Pharmaceuticals, Inc.ARWR	0%+0
5	MeiraGTx Holdings plcMGTX	0%new
6	ACHL - Achilles Therapeutics plc	——
7	Bicycle Therapeutics plc - ADRBCYC	0%0
8	Korro Bio Inc.KRRO	0%0
9	Oric Pharmaceuticals, Inc.ORIC	0%0
10	ORTX - Orchard Therapeutics plc	——

ProQR Therapeutics N.V. Ordinary Shares

Healthcare
Biotechnology

ProQR Therapeutics N.V. Ordinary Shares represent ownership in ProQR Therapeutics N.V., a clinical-stage biotechnology company focused on RNA-based medicines. ProQR develops therapies built on its Axiomer RNA editing platform, which is designed to address genetic disorders with unmet medical needs. Its current work centers on discovering and developing novel therapeutic candidates for severe rare diseases, with particular attention to inherited conditions and other genetic targets. The company operates in the biotechnology and healthcare sectors, where RNA medicine is an important area of research because it aims to modify disease-related genetic messages rather than conventional protein targets. ProQR Therapeutics N.V. serves as a specialized participant in the broader life sciences market, supporting research, clinical development, and potential commercialization pathways for next-generation genetic therapies. Headquartered in Leiden, the Netherlands, the company also maintains a presence in Cambridge, Massachusetts.

Website

Location

Zernikedreef 9

Leiden, 2333 CK

Netherlands

Social

What share of all stock conversation is about PRQR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0.02% +0.02	0% 0

Aug 20

BofA initiates coverage of PRQR with a Buy rating and a $8 target, citing positive AX-0810 Phase 1 data and strong RNA-editing upside.
The initiation of coverage by BofA is seen as a positive validation of PRQR's technology, with AX-0810 delivering the first human validation of Axiomer RNA tech.
Insiders have been making purchases in PRQR, which may indicate a reversal or bottoming in the stock.

Generated by AI

Sentiment

Of the messages about PRQR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	98.08% -1.92	96.25% -1.16	91.45% +6.73
Bearish	—	1.92% new	3.75% +1.16	8.55% -6.73

Bullish· Oct 23

$PRQR's strong pricing on its offering and Lilly's private placement provide a cash-rich platform for growth.
Lilly's decision to add more $PRQR shares to their pile, potentially based on inside information about preclinical results, is a bullish sign.
$PRQR's market capitalization remains undervalued compared to similar companies, with a strong close and demand that could drive the stock back up to its offering price.

Bearish· Oct 16

$PRQR has a history of being rejected at $4.00, potentially setting up an explosion through the $4.10 mark.
The company's 300 million shelf offering has not been raised, which could lead to a significant increase in the number of shares available.
The stock has been subject to aggressive short selling, with some traders covering their positions at lower prices.

Generated by AI

Topics

Of the messages about PRQR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	89.23%
Technical Analysis	—	0%	0%	3.95%
Analysts	—	0%	0%	6.68%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0.15%
Macro	—	0%	0%	0%

Analysts· Feb 14

Chardan Capital maintains a Buy rating for ProQR Therapeutics with a lower price target of $8.
JMP Securities lowers the price target for ProQR Therapeutics to $8 with a Market Outperform rating.
Analysts polled by Capital IQ have an average rating of Outperform for ProQR Therapeutics with price targets ranging from $3 to $20.

Announcements· Jun 25

ProQR Therapeutics ($PRQR) announces positive Phase 1 target engagement data for AX-0810, establishing the first clinical validation of its Axiomer RNA editing platform.
The company raises $50M in a registered direct offering priced at $1.81/share, with Eli Lilly participating in a concurrent private placement to maintain its ownership stake.
The positive data and funding raise demonstrate strong confidence in ProQR's RNA editing platform, with potential for faster pipeline progress and increased value for the company.

Technical Analysis· Dec 22

$PRQR is a high-volume stock that often holds its open level and closes green by 70% of the time.
$PRQR has a strong trend and has curled for a push through the Volume Weighted Average Price (VWAP).
$PRQR is forming a cup and handle pattern, with a potential target of $3.10-$9.00.

Generated by AI

Community

Of the messages about PRQR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	95.08%	1.25%	23.35%
Newcomers	—	4.92%	98.75%	76.65%

Regulars· Oct 16

ProQR's cash reserves are sufficient to last until 2026, and the company is on the verge of releasing preclinical data that will validate its platform and potentially exceed previous highs.
ProQR's ownership of key patents and its position as the inventor of RNA editing technology make it a significant player in the ADAR/RNA editing space, and its partnership with Lilly may provide a competitive advantage.
ProQR is expected to enter clinical trials in the current quarter or Q1, and its collaboration with Lilly and potential acquisition by Alnylam may be key factors in its future success.

Newcomers· Apr 9

$PRQR is up 12% after highlighting pipeline progress, including the selection of AX-0810 for Phase 2 biliary atresia trials.
ProQR's pipeline expansion is expected to bring multiple clinical catalysts, with target engagement data for AX-0810 due this quarter and a CTA for AX-0811 in mid-2026.
The company's investor and analyst event outlined its pipeline progress, focusing on key developments in its clinical trials and therapeutic pipeline.

Generated by AI

ProQR Therapeutics

Social

Aug 20

Bullish· Oct 23

Bearish· Oct 16

Analysts· Feb 14

Announcements· Jun 25

Technical Analysis· Dec 22

Regulars· Oct 16

Newcomers· Apr 9

ProQR names AI executives as clinical data nears

Obesity Market to Witness Strong Growth and Significant Market Expansion by 2036 – DelveInsight | Rhythm Pharma, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical

ProQR doses first participant in AX-0811 phase 1 trial

ProQR at Cantor conference: RNA editing pipeline gains speed

ProQR Therapeutics Doses First Participant in Phase 1 Trial of Liver Disease Treatment

ProQR to Participate in Upcoming Investor Conferences in September 2026

Also Discussed

ProQR Therapeutics N.V. Ordinary Shares

Company Information

Location

ProQR names AI executives as clinical data nears

Obesity Market to Witness Strong Growth and Significant Market Expansion by 2036 – DelveInsight | Rhythm Pharma, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical

ProQR doses first participant in AX-0811 phase 1 trial

ProQR at Cantor conference: RNA editing pipeline gains speed

ProQR Therapeutics Doses First Participant in Phase 1 Trial of Liver Disease Treatment

ProQR to Participate in Upcoming Investor Conferences in September 2026

Also Discussed

Social

Aug 20

Bullish· Oct 23

Bearish· Oct 16

Analysts· Feb 14

Announcements· Jun 25

Technical Analysis· Dec 22

Regulars· Oct 16

Newcomers· Apr 9